Skip to content
TrialMatch
Sign up
Recruiting Phase 2

Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma

Create a profile to match View the full record on ClinicalTrials.gov

About this study

This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .

Condition
Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Tested
Zanubrutinib, Rituximab, Venetoclax
Sponsor
Chinese PLA General Hospital

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 24

  • Minimum age: 18 years
  • Study condition: Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
  • A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated.
  • Stage II, III, or IV disease.
  • Able and willing to provide written informed consent and to comply with the study protocol.
  • at least one measurable disease.
  • Must be in need of therapy as evidenced by at least one of the following criteria:
  • Presence of at least one B symptom: Fever (\> 38 Celsius \[C\]) not due to infectious etiology, or Night sweats, or Weight loss \> 10% in the past 6 months;
  • Fatigue due to lymphoma;
  • Splenomegaly (\> 13 cm);
  • Compression syndrome (ureteral, orbital, gastrointestinal);
  • Any of the following cytopenias, due to lymphoma: Hemoglobin ≤ 10 g/dL, or Platelets ≤ 100 x 10\^9/L, or Absolute neutrophil count (ANC) \< 1.5 x 10\^9/L;
  • Pleural or peritoneal effusion;
  • Lactate dehydrogenase (LDH) \> upper limit of normal (ULN) or beta (B)2 microglobulin \> ULN;
  • Other lymphoma-mediated symptoms as determined by the treating physician.
  • ECOG ≤ 2
  • ANC \> 1.0 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
  • Platelet count \> 50 x 10\^9/L (for patients without bone marrow involvement by lymphoma)
  • Prothrombin time (PT)/international normal ratio (INR) \< 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time \[aPTT\]) \< 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder).
  • When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)
  • Serum aspartate transaminase (AST) and alanine transaminase (ALT) \< 3 x ULN
  • Creatinine clearance \> 30 ml/min calculated by modified Cockcroft-Gault formula
  • Bilirubin \< 1.5 x ULN unless bilirubin is due to Gilbert's syndrome, documented liver involvement with lymphoma, or of non-hepatic origin, in which case bilirubin should not exceed 3 g/dL
  • Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin \[B-hCG\]) pregnancy test at screening. Women who are pregnant or breastfeeding are ineligible for this study

Exclusion 7

  • Known active central nervous system lymphoma or leptomeningeal disease
  • Follicular lymphoma with evidence of diffuse large B-cell transformation
  • Grade 3b follicular lymphoma
  • Any prior history of other malignancy besides follicular lymphoma
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • Patients who have undergone major surgery within 14 days
  • The researchers believe that it is not advisable for the participant to take part in this trial.

Where

1 site, 1 recruiting

Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital

Beijing, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.